RESEARCH





Intra-ovarian injection of autologous menstrual blood-derived-mesenchymal stromal cells: a safe and promising method to improve pregnancy rate in poor ovarian responders

Simin Zafardoust^{1†}, Hamidreza Didar^{2†}, Maryam Ghasemi Ganagard², Maryam Tavakoli³, Soheila Arefi³, Shaghayegh Arjmandinaloo⁴ and Mina Fathi-Kazerooni^{1*}

Abstract

Background Poor ovarian response (POR) significantly reduces the success rates of fertility treatments. This study investigates the long-term efficacy and potential complications associated with autologous menstrual blood-derived mesenchymal stromal cells (MenSCs) therapy in improving fertility outcomes for women with POR.

Objective To evaluate the long-term efficacy and potential complications associated with MenSC therapy in improving fertility outcomes for women with POR.

Methods This longitudinal, single-center retrospective observational study included 105 POR patients who received autologous MenSC injections from August 2018 to September 2021. Participants were monitored for at least 3 years, and demographic, menstrual, and fertility data were collected. Potential complications were also assessed during this period. Statistical analyses were performed to determine pregnancy rates and possible complications.

Results The average age of participants at the time of injection was 37.91 years. During the follow-up period, 36.19% of women became pregnant, with a live birth rate of 30.48% per treatment cycle. The treatment showed no significant difference in pregnancy rates between women with regular and irregular menstrual cycles. The spontaneous pregnancy rate was also notably higher within the first three months post-injection. No significant complications such as endometriosis, ovarian malignancies, or autoimmune disorders were observed. Only one case of an ovarian cyst, which resolved without intervention, was reported. MenSC treatment did not increase the risk of congenital anomalies or infant mortality.

Conclusion Intra-ovarian injection of MenSCs is a safe and promising method for improving pregnancy outcomes in women with POR.

Keywords Poor ovarian response (POR), Menstrual blood-derived stem cells (MenSCs), Intra-ovarian injection, Stem cell therapy, Long-term safety

[†]Simin Zafardoust and Hamidreza Didar are equally the first authors of the article.

*Correspondence: Mina Fathi-Kazerooni minafathi30@yahoo.com; m.fathi@avicenna.ac.ir Full list of author information is available at the end of the article



© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Content courtesy of Springer Nature, terms of use apply. Rights reserved.

Introduction

Poor ovarian response (POR) refers to a suboptimal response of the ovaries during the in vitro fertilization (IVF) or other assisted reproductive techniques. [1] According to Bologna criteria developed by the European Society of Human Reproduction and Embryology (ESHRE) in 2011, at least two of the following criteria are necessary to be considered as a poor ovarian responder:

- 1. Advanced maternal age (>40 years).
- 2. Previous POR: cancelation of cycles or retrieval of three or fewer oocytes using a conventional stimulation protocol.
- 3. Abnormal ovarian reserve tests (ORT):
- 4. Anti-Mullerian hormone (AMH): Less than 0.5–1.1 ng/ml
- 5. Antral follicle count (AFC): Less than 5–7 follicles. [2]

Poor ovarian response presents significant challenges for individuals undergoing fertility treatments. Reduced chance of pregnancy: due to a decrease in mature follicles, Higher cancellation rate because of Inadequate follicle development, Financial burden as Multiple IVF attempts can be costly, and Emotional toll of repeated IVF failures can be significant. Addressing POR remains a complex task, providing compassionate care and support to those dealing with poor ovarian response is crucial. [3]

Despite the challenges, researchers and clinicians seek different treatment options including Growth hormone supplementations, Controlled Ovarian Hyperstimulation, adjunct therapy, acupuncture, and intra-ovarian injection of platelet-rich plasma. [4–8]

Numerous studies have explored the potential of stem cells in improving ovarian function. Menstrual bloodderived stem cells (MenSCs) have emerged as a fascinating source of mesenchymal stem cells (MSCs) with unique properties. [9] Although they may not directly differentiate to follicular cells, MenSCs play a crucial role in modulating immune responses. They can suppress inflammation and promote tissue repair in inflammatory diseases, tumors, and tissue injuries. [9, 10] MenSCs hold promise for treating infertility and ovarian dysfunction. Their ability to enhance folliculogenesis, regulate angiogenesis, and reduce ovarian stromal fibrosis makes them valuable for improving ovarian health. [11] Men-SCs contribute to tissue repair and potential fertility restoration by improving the ovarian stromal environment. [12] MSCs can be sourced from various locations in the body, including bone marrow, adipose tissue, umbilical cord, and menstrual blood. [13] Unlike bone marrow or adipose tissue, MenSCs can be collected monthly during menstruation without invasive procedures, ethical concerns, and autoimmune rejection. [14]

In the previous phases of our clinical trial, we concluded that potential hazards associated with MSC application, particularly in specific cellular microenvironments, necessitate careful long-term monitoring and follow-up assessments. We emphasized the need for further randomized parallel studies with larger sample sizes and extended follow-up periods to definitively establish the impact of MenSCs on ovarian function and live birth rates. In this follow-up study, conducted years after the initial trial, our goal was to adhere to these recommendations by monitoring our patients' long-term efficacy and potential complications of MenSC therapy. [15, 16]

Method

Study design

This investigation constitutes a longitudinal, national single-center retrospective observational study encompassing all patients diagnosed with POR (n=105) who underwent autologous MenSCs administration across three distinct phases of clinical trials from August 2018 to September 2021 [15, 16]. The detailed study protocol, selection criteria, and methodologies of cell therapy for POR patients have been articulated in preceding publications [15, 16]. Authorization for the clinical trial protocol and the associated consent documentation was obtained from the Biomedical Research Ethics Committee of the Academic Center for Education, Culture, and Research (ACECR). Patients participated in clinical evaluations at the Avicenna Fertility Center approximately at intervals of 3 months, 6 months, and 1-year post-cell therapy. Subsequently, they were directed to local facilities for annual evaluations, and pertinent medical information was extracted from their medical records. Following a minimum follow-up duration of 3 years (ranging from 3 to 6 years), a comprehensive questionnaire was developed, and a trained midwifery professional contacted all patients to collect the requisite information.

Data collection

We collected demographic and relevant information from electronic patient records and our previous publications. This included details such as age, number of injections, injection dates, pre/ post injection menstrual states, and IVF outcomes. [15, 16]

Every participant was assessed utilizing a long-term safety and efficacy assessment methodology. This technique involved analyzing the patient's medical history, imaging investigations, laboratory test results, and selfreported information to ascertain any problems, menstruation status, fertility status, pregnancy outcomes, and neonatal follow-up information. Two specialists meticulously examined the checklist items, leveraging their expertise in patient complications and fertility outcomes during the assessment. Before the initiation of interviews, informed oral consent was obtained from all participants, who were apprised of the study's objectives, their entitlements, and the voluntary nature of their participation. The confidentiality of the participants was assured, and they were invited to pose inquiries before granting their consent.

Study inquiries

The follow-up protocol encompassing the checklist entailed inquiries regarding the overall survival rates of both mothers and infants, along with newly diagnosed conditions in patients, including but not limited to ovarian cysts, ovarian carcinoma, endometrioma, endometriosis, ovarian torsion, and breast cancer. Furthermore, we solicited information regarding pelvic inflammatory disease, systemic lupus erythematosus, rheumatoid arthritis, other autoimmune disorders, and any subjective health issues that may manifest as potential long-term complications.

In instances where an infant was delivered as a result of this methodology, we sought information concerning the growth and physical health of the infants as well as potential adverse outcomes, which included mortality within the initial year, childhood malignancies (such as leukemia and lymphoma), thyroid dysfunction, congenital anomalies, autism spectrum disorders, and other selfreported health concerns.

To evaluate menstrual health, we probed into the regularity of menstrual cycles and the menopausal status of individuals. To monitor fertility rates and pregnancy outcomes, we inquired about spontaneous pregnancies and pregnancies achieved through Assisted Reproductive Technology (ART).

Statistical analysis

All statistical analyses and graphical representations were performed using the R statistical package. Demographic data, menstrual status, and pregnancy outcomes were summarized using descriptive statistics. Continuous variables were reported as mean \pm standard deviation (SD), while categorical variables were expressed as frequencies and percentages. Associations between categorical variables were evaluated using Pearson's Chi-squared test with Yates' continuity correction. All statistical tests were two-tailed, with a significance level set at p < 0.05.

Results

Participant demographics

A total of 105 women who received intraovarian injections of MenSCs due to poor ovarian response were monitored. The average age of these patients was 37.91 years (ranging from 24 to 45) at the time of injection, which increased to 41.98 years during the follow-up period. Of the participants, 70 received a single injection, while 35 received two injections. The average duration of follow-up from the last injection was 3.72 years, with the minimum follow-up being 2.5 years and the maximum extending to 6 years Table 1.

Menstrual status

At the time of the injection, 91 women were experiencing regular menstrual cycles. During the follow-up period, 12 of these women (13.1%) reported irregular menstrual patterns, and 1 woman (1.9%) had entered menopause. Of the 24 women who initially had irregular menstrual cycles, 6 (25%) reported a return to regular cycles at follow-up, while 4 (16%) had undergone menopause Table 1.

Fertility and pregnancy outcomes

Among 105 poor ovarian responders, 38 women (36.19%) became pregnant, with 27 achieving pregnancy spontaneously, 13 through IVF, and 2 through both methods. 27 women (25.7%) with poor ovarian response became pregnant spontaneously after the injection. One woman became pregnant twice, and another became pregnant three times. The median time to spontaneous pregnancy was 3 months post-injection, with a range from 1 to 24 months. Of the 54 women who underwent IVF after their injection, 13 (24%) became pregnant. One case had twin pregnancies. The median time after injection for a successful IVF was 5,5 months, with a range from 2 to 13 months Fig. 1.

Impact of Age on Outcomes: To assess the impact of age on pregnancy outcomes, patients were divided into two groups: under 35 and 35 or older. Among the 23 women under 35, 12 (52.17%) became pregnant. In contrast, among the 82 women aged 35 or older, 26 (31.7%)

| Table 1 | Demographic (| Characteristics | of women | received |
|---------|---------------|-----------------|----------|----------|
| MenSC i | njection | | | |

| Characteristics | Values | |
|---------------------------------|------------|--|
| Age by First Injection | 37.91±4.98 | |
| Age by the time of follow-up | 41.98±5.00 | |
| Follow-Up Duration (Year) | 3.14 | |
| Menses Before Injection | | |
| Regular | 91 | |
| Irregular | 14 | |
| Menses at the time of follow-up | | |
| Regular | 84 | |
| Irregular | 16 | |
| Menopause | 5 | |
| | | |



Fig. 1 Pregnancy outcome by method. Distribution of Pregnancy Outcomes by Months After MenSC Injection. The median time to pregnancy after MenSC injection was 3 months for spontaneous pregnancies and approximately 5.5 months for IVF pregnancies

became pregnant. Pearson's Chi-squared test with Yates' continuity correction indicated no significant difference between the two groups (X-squared=2.4321, df=1, p-value=0.1189). As shown in Fig. 2, the box plot provides a visual summary of the age distribution among the participants. The median age for pregnancy was 36 years, with the whiskers extending from age 24 to age 42, highlighting the overall age spread Table 2.

Menstrual Status Impact on Outcome The impact of menstrual status on treatment outcomes was assessed by comparing pregnancy rates between women with regular and irregular cycles. It was found that, among the 91 patients with regular cycles at the time of injection, 33 (36.26%) became pregnant. In contrast, pregnancy was achieved by 5 out of 14 women (35.7%) with irregular cycles. No significant difference between the two groups was indicated by Pearson's Chi-squared test with Yates' continuity correction (X-squared=6.0062e-31, df=1, p-value=1) Table 2.

Injection Type Distribution 70 women received a single injection, with 29 achieving pregnancy. On the other hand, 35 women received a second injection after the first one, and 9 of them became pregnant. (Table 2).

Complications

Among all the women who were followed up,1 case of an ovarian cyst during pregnancy was reported, which resolved after pregnancy and by the time of follow-up. There were no reports of other complications such as endometriosis, endometrioma, ovarian malignancy, ovarian torsion, pelvic inflammatory disease (PID), ectopic pregnancy (EP), or autoimmune diseases Table 3.

Baby outcome

Of the 105 women who were part of the research, 43 pregnancies were documented, with 38 of them becoming pregnant, some more than once. Out of these pregnancies, 12 resulted in abortion, while 31 pregnancies were successful, leading to live births. Notably, one of these successful pregnancies resulted in twins, bringing the total number of live births to 32. Based on the total number of women, the live birth rates each treatment cycle was determined to be 30.48%, and the live birth rate per pregnancy, which represents the proportion of successful births among all pregnancies, was 74.42%. Despite the possibility of some pregnancy losses, these results show a positive live birth outcome, with most pregnancies ending in live births Table 3.

Discussion

This study explored the outcomes of intraovarian injections of MenSCs in 105 women with poor ovarian response, with a focus on pregnancy, live birth rates, and potential complications. Notably, no significant



Fig. 2 Age Distribution of Women with POR. Age Distribution of Women Who Got Pregnant Following MenSC Injection. The ages of women who became pregnant after MenSC injection ranged from 24 to 43 years, with a median age of 36 years

| Factor | Pregnancy/Total | Percentage | Chi-squared Value | <i>p</i> -value | |
|----------------------------|-----------------|------------|-------------------|-----------------|--|
| Pregnant Women | 38/105 | 36.19 | | | |
| Impact of Age | | | | | |
| < 35 years | 12/23 | 52.17 | | | |
| ≥ 35 years | 26/82 | 31.7 | 2.4321 | 0.11* | |
| Impact of Menstrual Status | | | | | |
| Regular Menses | 33/91 | 36.2 | | | |
| Irregular Menses | 5/14 | 35.7 | 6.0062e-31 | 1** | |
| Injection Type | | | | | |
| Single Injection | 29/70 | 41.4 | | | |
| Double Injection | 9/35 | 25.71 | | | |

 Table 2
 The impact of different factors on stem cell treatment outcome

pregnancy outcomes based on various factors. *The difference between pregnancy rates for women over 35 years and those under 35 years was not significant (p-value = 0.11). **Menstrual status prior to injection does not significantly impact

long-term problems were noted over an average followup time of 3.72 years. Only one case of an ovarian cyst during pregnancy was documented, which resolved without intervention. There were no instances of endometriosis, ovarian malignancies, torsion, pelvic inflammatory disease, ectopic pregnancies, or autoimmune disorders. These findings suggest that intraovarian injections of MenSCs are a safe, long-term treatment option for women with poor ovarian response, with a low complication profile even years after treatment.

In terms of fertility outcomes, 36.19% of women became pregnant, with a live birth rate of 30.48% per treatment cycle and 74.42% per pregnancy. The data also highlight that age was a key determinant of success, with women under 35 showing significantly higher odds of pregnancy. In contrast, menstrual status (regular

| Women's Complications | N=105 | Fetus/ Neonatal Complications | N=43 |
|-----------------------------|-------|-------------------------------|------|
| Ovarian Cyst | 1 | Abortion | 12 |
| Ovarian Torsion | 0 | Died within the First Year | 0 |
| Endometrioma | 0 | Leukemia | 0 |
| Endometriosis | 0 | Autism | 0 |
| Ovarian Malignancy | 0 | Childhood Cancer | 0 |
| Pelvic Inflammatory Disease | 0 | Thyroid Disorder | 0 |
| Ectopic Pregnancy | 0 | Congenital Anomalies | 0 |
| Autoimmune Diseases | 0 | Other | 0 |

Table 3 Women, Fetal, and Neonatal Complications Following MenSC Injection

vs. irregular) did not significantly impact pregnancy outcomes.

When exploring new methods for treating poor ovarian response, it's essential to consider factors such as efficacy, safety, accessibility, and cost-effectiveness. Stem cell therapy has demonstrated promise in treating infertility. [17] The remarkable ability of Menstrual Stem Cells (Men-SCs) to undergo proliferation and differentiation makes them an excellent choice for enhancing ovarian function in the long term. These cells can differentiate into various cell types, including follicular cells and even oocytelike cells, which positions them as a valuable option for addressing diminished ovarian reserve. [18, 19]

Our study followed 105 women who underwent intraovarian injection of MenSCs due to poor ovarian response. While a meta-analysis by Máté Éliás et al. (2023) indicated a spontaneous pregnancy rate of 7% following intra-ovarian injection of platelet-rich plasma (PRP) in poor ovarian responders, our study found a significantly higher spontaneous pregnancy rate of 25.7% following intraovarian injection of MenSCs. [20] Another metaanalysis by Vahabi Dastjerdi et al. on the effect of intraovarian PRP injection showed a 5% rate of spontaneous pregnancy in poor ovarian responders. [21] This difference could be attributed to the fact that, Unlike MenSCs, which can proliferate and differentiate, PRP primarily works by releasing growth factors that can temporarily enhance ovarian function. [22, 23] The pregnancy rate achieved through IVF after injection of MenSCs was 24%, with a live birth rate of 16.6%. In comparison, a study by Cakiroglu et al. that included 510 women with poor ovarian response who were treated with intraovarian injection of autologous PRP reported a pregnancy rate of 17% and a live birth rate of 11.4%. [24] A systematic review of 10 studies on women with POR treated with intraovarian PRP injection showed a clinical pregnancy rate of 25.4% and a live birth rate of 16.6%. [8] In our study, we achieved higher rates, with a 36.15% pregnancy rate and a 30.48% live birth rate. These findings suggest that the intraovarian injection of menstrual blood-derived mesenchymal stromal cells (MenSCs) may be more effective than PRP treatment for women with POR.

In this study, it was observed that women who received a single injection had a higher pregnancy rate (41.4%, 29 out of 70) compared to those who received a double injection (25.71%, 9 out of 35). While this suggests that a single injection may be associated with a higher likelihood of pregnancy, it is important to note that the second injection was typically administered to women who did not achieve pregnancy after the first injection, often following their insistence. These women's chances of becoming pregnant may have been affected by their initial worse prognosis. Therefore, the lower pregnancy rate in the double injection group does not necessarily indicate that two injections were less effective. On the contrary, the fact that some women did conceive after the second injection suggests that it had a positive impact on pregnancy outcomes for those who initially had a poor response. This highlights the potential value of a second injection as a supplementary option for women who do not respond to the initial treatment.

Our analysis showed that menstrual status did not significantly impact pregnancy outcomes. Among women with regular cycles, 36.26% became pregnant, compared to 35.7% of those with irregular cycles (p=1). Even women with irregular cycles had comparable pregnancy rates, indicating that treatment may be effective regardless of cycle regularity. This highlights the need for further research to identify other factors that may play a more critical role in fertility outcomes.

The median time to spontaneous pregnancy after MenSCs injection was observed to be 3 months, and the median time to pregnancy through IVF was 5 months, aligning with most studies on PRP injections that report effects within 1 to 6 months. [8, 25–27]

Interestingly, a large proportion of spontaneous pregnancies occurred within the first 3 months following the MenSCs injection. It could be wise to wait at least three months before starting IVF therapy in light of this tendency. This finding implies that MenSCs' beneficial effects on ovarian function may start to show around this period. Starting IVF too early may overlook the potential for spontaneous pregnancy, as ovarian responsiveness could improve naturally within this window. Therefore, a 3-month waiting period post-injection before considering IVF may optimize the treatment's impact on fertility outcomes, allowing for the possibility of natural conception while still leaving IVF as a subsequent option for those who do not conceive spontaneously.

The lack of long-term follow-up studies on PRP injections makes it challenging to compare the long-term efficacy of these treatments. However, our findings show that several cases of MenSCs injections resulted in pregnancies even after one year, with two cases achieving pregnancy after two years. This suggests that MenSCs may have a prolonged effect on ovarian function compared to PRP. Future research should focus on extended follow-up periods to better understand the sustained impact of both PRP and MenSCs injections on fertility outcomes in poor ovarian responders. [20, 28]

Complications

MenSCs exhibit impressive differentiation capabilities, including the potential to become adipocytes, chondrocytes, osteogenic cells, fibroblasts, endometrial cells, and germ cell-like structures. [29, 30] Retrograde menstruation, a widely accepted pathophysiological mechanism of endometriosis, involves the backward flow of shed endometrial cells. [31] Hypotheses suggest that mesenchymal stromal stem cells from menstrual blood, carried by retrograde menstruation, play a role in endometriosis development by differentiating outside the uterus. [32, 33] Contrary to initial expectations, our findings suggest that injecting these cells into the ovaries does not increase the risk of endometrioma and endometriosis for the patient. Recent research highlights endometriosis as a systemic disease influenced by various factors. [34] These include immune system dysregulation, disrupted signaling pathways, and hormonal imbalances. [35-37] Notably, Men-SCs exhibit distinct characteristics between women with and without endometriosis, including differences in gene expression, morphology, cluster of differentiation (CD) markers, and immunomodulatory molecules. [38–40] This suggests that injecting MenSCs derived from women with endometriosis could potentially cause endometriosis. [41] Consequently, cautious utilization of MenSCs in patients with endometriosis is crucial, and further comprehensive studies are warranted.

Fibrosis is a potential complication and adverse effect of stem cell injection, with reports indicating liver, cardiac, and renal interstitial fibrosis due to the potential differentiation of stem cells into fibroblast cells. [42, 43] A study by Gu et al. reported that ovarian fibrosis, which can manifest as decreased ovarian function, is caused by the excessive proliferation of fibroblasts and their activity in producing transforming growth factor beta (TGF- β) and extracellular matrix (ECM). [44] In our study, we observed that a noteworthy portion of women with initially irregular menstrual cycles reported regular cycles at follow-up, suggesting a positive impact of the injection on menstrual regularity and ovarian function. However, the development of irregular cycles or menopause in some women with initially regular cycles highlights the natural progression of ovarian aging and the variability in individual responses. [45, 46] In our follow-up to identify any long-term complications, there were no reports of issues as a probable consequence of intra-ovarian Men-SCs injection, except for a case of an ovarian cyst during pregnancy, which resolved on its own. Studies indicate that ovarian cysts are common during pregnancy, and the majority of these cysts are benign and resolve spontaneously. [47-49]

Our findings suggest that MenSCs treatment does not carry the same increased risk of infant complications observed with other treatment methods. This underscores the potential safety of MenSCs therapy not only for the mothers but also for the infants born through this method.

A comprehensive study conducted in Sweden revealed that babies conceived through ART have a 45% increased risk of mortality within the first year of life, depending on the specific type of ART, when compared to naturally conceived infants. [50] Our study found that none of the babies born, whether through spontaneous pregnancy or IVF, died within the first year.

Additionally, research indicates that infants conceived through ART have a slightly elevated risk of nonchromosomal birth defects compared to naturally conceived babies. [51] Major congenital anomalies are generally recognized at birth, while minor ones might go unnoticed initially, with most significant congenital anomalies typically identified during the first year of life. [52] In our study, there were no reports of congenital anomalies, defects, or other problems.

Strengths and limitations

This study has several strengths that support the conclusion of the safety and long-term efficacy of intraovarian MenSCs injection. The number of participants who underwent the procedure, along with the extensive follow-up period, provided robust data to assess both short-term and long-term outcomes. All potential complications, based on the differentiation capabilities of MenSCs, were thoroughly considered and investigated. Additionally, all babies conceived through this method were closely monitored to ensure there were no negative outcomes associated with the intervention for the babies.

However, this study also has some limitations. One significant limitation is the lack of long-term pregnancy outcome data for the control group from previous studies, which could have provided a more comprehensive comparison. Another limitation of this study was the inability to invite all participants to our center for direct, in-person evaluation of long-term complications. Many of the women were residing in various cities, and access to the center was limited. As a result, we relied on medical follow-up sessions conducted over the years through their local healthcare providers and supplemented this with self-reported telephone interviews. While this approach allowed us to maintain contact with participants and collect necessary data, it may not have been as precise or comprehensive as regular in-person assessments conducted at our center. Future studies would benefit from more consistent and standardized follow-up methods, such as in-person visits, to ensure a more accurate evaluation of long-term outcomes.

Conclusion

The use of MenSCs represents a safe and promising avenue for improving pregnancy outcomes in women with poor ovarian response. However robust evidence is needed to validate its efficacy and safety. Rigorous studies and clinical trials are essential to establish MenSC therapy's effectiveness. We encourage researchers to consider some suggestions including:

- *Cell Differentiation* Exploring MenSC differentiation into specific cell types (e.g., follicular structures or fibroblasts) before injection may enhance therapeutic outcomes.
- Co-Administration of Factors Co-administering cytokines or growth factors alongside MenSCs could optimize tissue repair.
- *Adjunct Therapies* Beyond intra-ovarian injection, adjunct therapies should be explored.
- Personalized Approach Tailoring therapy based on individual patient profiles may maximize success.

Abbreviations

| POR | Poor ovarian response |
|--------|---------------------------------------|
| MenSCs | Menstrual blood-derived stromal cells |
| IVF | In vitro fertilization |
| ORT | Ovarian reserve tests |
| AMH | Anti-Müllerian hormone |
| AFC | Antral follicular count |
| MSC | Mesenchymal stem cell |
| ART | Assisted reproductive technology |
| PID | Pelvic inflammatory disease |
| EP | Ectopic pregnancy |

 PRP
 Platelet-rich plasma

 CD
 Cluster of differentiation

 ECM
 Extracellular matrix

 TGF-β
 Transforming growth factor beta

ECM Extracellular matrix

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s13287-025-04278-6.

Additional file 1.

Additional file 2.

Acknowledgements

The authors would like to appreciate Dr. Somaieh Kazemnejad, the corresponding author of the previous three phases of this study, Miss Maryam Darzi (Production Manager), Mrs. Somayeh Khorasani (production line assistant), Mrs. Zohreh Fathi (supervisor of the embryology lab), and Mrs. Fariba Mohammadi (supervisor of the operation room) for their assistance in the implementation of this project. The authors declare that they have not used Al-generated work in this manuscript.

Author contributions

SZ: Designed the study, supervised the project, and critically reviewed the manuscript for important intellectual content. HD: Contributed to the conception and design of the study, performed data collection, analysis, and interpretation, and drafted the manuscript. MGG: Provided clinical expertise, contributed to patient recruitment, and reviewed the manuscript. MT: Involved in statistical analysis and interpretation of the data, and helped in drafting the manuscript. SA: Contributed to the design of the study and supervised the project. SA: Involved in the interpretation of the data, and helped in drafting the manuscript. MFK: Assisted in the literature review, contributed to writing sections of the manuscript, and reviewed the final draft.

Funding

This study was financially supported by Avicenna Research Institute (Grant Number: 990304–008). The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

All of the data generated and analyzed during this study are included in the manuscript.

Declarations

Ethics approval and Consent to participate

The study was started after providing complete information to patients and obtaining signed written consent. This clinical study was conducted with the permission of the Ethics Committee for Biomedical Research of the Academic Center for Education, Culture, and Research (ACECR, Tehran, Iran) (IRACECR. REC.1397.002, 2018–05-06 and IRACECR.REC.1399.002, 2020–05-31) under the title "Evaluation of the safety and feasibility of intra-ovarian injection of menstrual blood stem cells in women with poor ovarian responders (POR)". All procedures observed were under the Declaration of Helsinki, Good Clinical Practice (GCP), and GMP guidelines. Furthermore, this study was registered with the Iranian Clinical Trials Registry (IRCT20180619040147N2) and ClinicalTrials.gov (NCT05703308). The cell manufacturing was performed by STERCO (Tehran, Iran) in a GMP clean room authorized by Iran Food and Drug Administration authorities.

Consent for publication

Not relevant.

Competing of interests

The authors declare that they have no competing interests.

Content courtesy of Springer Nature, terms of use apply. Rights reserved.

Author details

¹Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. ²Avicenna Fertility Clinic, Avicenna Research Institute, ACECR, Tehran, Iran. ³Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. ⁴The Faculty of Science and New Biological Technologies, University of Science and Culture, Tehran, Iran.

Received: 23 December 2024 Accepted: 12 March 2025 Published online: 12 April 2025

References

- Abu-Musa A, Haahr T, Humaidan P. Novel physiology and definition of poor ovarian response; clinical recommendations. Int J Mol Sci. 2020;21(6):2110.
- Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of 'poor response to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–24.
- Giannelou P, Simopoulou M, Grigoriadis S, Makrakis E, Kontogeorgi A, Pantou A, et al. The conundrum of poor ovarian response: from diagnosis to treatment. Diagnostics. 2020;10(9):687.
- Lin G, Zhong X, Li S, Xu L. Clinical evidence of growth hormone for infertile women with diminished ovarian reserve undergoing IVF: a systematic review and meta-analysis. Front Endocrinol. 2023;14:1215755.
- Duan X, Li Z, Li M, Ma X. Analysis of controlled ovarian hyperstimulation protocols in women over 35 years old with poor ovarian response: a realworld study. BMC Pregnancy Childbirth. 2023;23(1):813.
- Wang R-R, Su M-H, Liu L-Y, Lai Y-Y, Guo X-L, Gan D, et al. Systematic review of acupuncture to improve ovarian function in women with poor ovarian response. Front Endocrinol. 2023;14:1028853.
- Di Guardo F, Pluchino N, Drakopoulos P. Treatment modalities for poor ovarian responders. Ther Adv Reprod Health. 2023;17:26334941221147464.
- Wu L, Su F, Luo P, Dong Q, Ma M, Ye G. The efficacy of platelet rich plasma on women with poor ovarian response: a systematic review and metaanalysis. Platelets. 2024;35(1):2292612.
- Mohamed Rasheed ZB, Nordin F, Wan Kamarul Zaman WS, Tan Y-F, Abd Aziz NH. Autologous human mesenchymal stem cell-based therapy in infertility: New strategies and future perspectives. Biology. 2023;12(1):108.
- Zhang S, Yahaya BH, Pan Y, Liu Y, Lin J. Menstrual blood-derived endometrial stem cell, a unique and promising alternative in the stem cell-based therapy for chemotherapy-induced premature ovarian insufficiency. Stem Cell Res Ther. 2023;14(1):327.
- Kuchakzadeh F, Ai J, Ebrahimi-Barough S. Tissue engineering and stem cell-based therapeutic strategies for premature ovarian insufficiency. Regen Ther. 2024;25:10–23.
- 12. Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther. 2017;8:1–14.
- Costela-Ruiz VJ, Melguizo-Rodríguez L, Bellotti C, Illescas-Montes R, Stanco D, Arciola CR, et al. Different sources of mesenchymal stem cells for tissue regeneration: a guide to identifying the most favorable one in orthopedics and dentistry applications. Int J Mol Sci. 2022;23(11):6356.
- 14. Zhao Y-x, Chen S-r, Su P-p, Huang F-h, Shi Y-c, Shi Q-y, et al. Using mesenchymal stem cells to treat female infertility: an update on female reproductive diseases. Stem Cells Int. 2019;2019(1):9071720.
- 15. Zafardoust S, Kazemnejad S, Darzi M, Fathi-Kazerooni M, Rastegari H, Mohammadzadeh A. Improvement of pregnancy rate and live birth rate in poor ovarian responders by intraovarian administration of autologous menstrual blood derived-mesenchymal stromal cells: phase I/II clinical trial. Stem cell Rev Rep. 2020;16:755–63.
- Zafardoust S, Kazemnejad S, Fathi-Kazerooni M, Darzi M, Sadeghi MR, Sadeghi Tabar A, et al. The effects of intraovarian injection of autologous menstrual blood-derived mesenchymal stromal cells on pregnancy outcomes in women with poor ovarian response. Stem Cell Res Ther. 2023;14(1):332.
- Chang CL. Facilitation of ovarian response by mechanical force: latest insight on fertility improvement in women with poor ovarian response or primary ovarian insufficiency. Int J Mol Sci. 2023;24(19):14751.

- Manshadi MD, Navid S, Hoshino Y, Daneshi E, Noory P, Abbasi M. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure. Microsc Res Tech. 2019;82(6):635–42.
- Sheikholeslami A, Kalhor N, Sheykhhasan M, Jannatifar R, Sahraei SS. Evaluating differentiation potential of the human menstrual bloodderived stem cells from infertile women into oocyte-like cells. Reprod Biol. 2021;21(1): 100477.
- Éliás M, Kónya M, Kekk Z, Turan C, das Virgens IPA, Tóth R, et al. Plateletrich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis. J Ovar Res. 2024;17(1):104.
- 21. Vahabi Dastjerdi M, Sheibani S, Taheri M, Hezarcheshmeh FK, Jahangirian J, Jazayeri M, et al. Efficacy of intra-ovarian injection of autologous platelet-rich plasma in women with poor responders: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024;309(6):2323–38.
- 22. Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet rich plasma: a short overview of certain bioactive components. Open Med. 2016;11(1):242–7.
- Hosseinisadat R, Nejad AF, Mohammadi F. Intra-ovarian infusion of autologous platelet-rich plasma in women with poor ovarian reserve: a before and after study. Eur J Obstet Gynecol Reprod Biol. 2023;280:60–3.
- Cakiroglu Y, Yuceturk A, Karaosmanoglu O, Kopuk SY, Korun ZEU, Herlihy N, et al. Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP). Aging. 2022;14(6):2513.
- Safarova S, Akdulum MFC, Guler I, Bozkurt N, Erdem A, Karabacak RO. Does platelet-rich plasma treatment increase in vitro fertilization (IVF) success in the infertile population? Cureus. 2023;15(10).
- Pantos K, Simopoulou M, Pantou A, Rapani A, Tsioulou P, Nitsos N, et al. A case series on natural conceptions resulting in ongoing pregnancies in menopausal and prematurely menopausal women following plateletrich plasma treatment. Cell Transpl. 2019;28(9–10):1333–40.
- 27. Pacu I, Zygouropoulos N, Dimitriu M, Rosu G, Ionescu CA. Use of plateletrich plasma in the treatment of infertility in poor responders in assisted human reproduction procedures. Exp Ther Med. 2021;22(6):1–6.
- Adiga PK, Marconi N, N R, Vitthala S. Effect of intra-ovarian injection of platelet-rich plasma on the patients with a poor ovarian response (POR) or premature ovarian insufficiency (POI): a systematic review and metaanalysis. Middle East Fertil Soc J. 2024;29(1):24.
- Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther. 2019;10:1–12.
- Lai D, Guo Y, Zhang Q, Chen Y, Xiang C. Differentiation of human menstrual blood-derived endometrial mesenchymal stem cells into oocytelike cells. Acta Biochim Biophys Sin. 2016;48(11):998–1005.
- 31. Lamceva J, Uljanovs R, Strumfa I. The main theories on the pathogenesis of endometriosis. Int J Mol Sci. 2023;24(5):4254.
- 32. Signorile PG, Viceconte R, Baldi A. New insights in pathogenesis of endometriosis. Front Med. 2022;9: 879015.
- Cordeiro MR, Carvalhos CA, Figueiredo-Dias M. The emerging role of menstrual-blood-derived stem cells in endometriosis. Biomedicines. 2022;11(1):39.
- Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. The Lancet. 2021;397(10276):839–52.
- Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, et al. Immunological basis of the endometriosis: the complement system as a potential therapeutic target. Front Immunol. 2021;11: 599117.
- Zhang M, Xu T, Tong D, Li S, Yu X, Liu B, et al. Research advances in endometriosis-related signaling pathways: a review. Biomed Pharmacother. 2023;164: 114909.
- Marquardt RM, Kim TH, Shin J-H, Jeong J-W. Progesterone and estrogen signaling in the endometrium: What goes wrong in endometriosis? Int J Mol Sci. 2019;20(15):3822.
- Nikoo S, Ebtekar M, Jeddi-Tehrani M, Shervin A, Bozorgmehr M, Vafaei S, et al. Menstrual blood-derived stromal stem cells from women with and without endometriosis reveal different phenotypic and functional characteristics. Mol Hum Reprod. 2014;20(9):905–18.
- Sahraei SS, Kowsari A, Asl FD, Sheykhhasan M, Naserpoor L, Sheikholeslami A. Evaluating the effect of conditioned medium from endometrial

stem cells on endometriosis-derived endometrial stem cells. Anat Cell Biol. 2022;55(1):100–8.

- 40. Sahraei SS, Davoodi Asl F, Kalhor N, Sheykhhasan M, Fazaeli H, Moud SS, et al. A comparative study of gene expression in menstrual blood-derived stromal cells between endometriosis and healthy women. Biomed Res Int. 2022;2022(1):7053521.
- Zhang Y, He T, Lin T, Guo Q, Huo C, Roberts SZ, et al. Novel in vivo endometriotic models associated eutopic endometrium by implanting menstrual blood-derived stromal cells from patients with endometriosis. Sci Rep. 2023;13(1):8347.
- Baranovskii DS, Klabukov ID, Arguchinskaya NV, Yakimova AO, Kisel AA, Yatsenko EM, et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investig. 2022. https:// doi.org/10.21037/sci-2022-025.
- Kim J-S, Lee J-H, Kwon O, Cho J-H, Choi J-Y, Park S-H, et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney Res Clin Pract. 2017;36(2):200.
- 44. Gu M, Wang Y, Yu Y. Ovarian fibrosis: molecular mechanisms and potential therapeutic targets. J Ovar Res. 2024;17(1):139.
- Broekmans F, Soules M, Fauser B. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009;30(5):465–93.
- Wang X, Wang L, Xiang W. Mechanisms of ovarian aging in women: a review. J Ovar Res. 2023;16(1):67.
- Bhagat N, Gajjar K. Management of ovarian cysts during pregnancy. Obstet Gynaecol Reprod Med. 2022;32(9):205–10.
- Senarath S, Ades A, Nanayakkara P. Ovarian cysts in pregnancy: a narrative review. J Obstet Gynaecol. 2021;41(2):169–75.
- Zvi MB, Thanatsis N, Vashisht A. Ovarian cysts in pregnancy. In: Jha S, Madhuvrata P, editors. Gynaecology for the obstetrician. Cambridge University Press; 2023. p. 1–13. https://doi.org/10.1017/9781009208802.003.
- Rodriguez-Wallberg KA, Lundberg FE, Ekberg S, Johansson AL, Ludvigsson JF, Almqvist C, et al. Mortality from infancy to adolescence in singleton children conceived from assisted reproductive techniques versus naturally conceived singletons in Sweden. Fertil Steril. 2020;113(3):524–32.
- Boulet SL, Kirby RS, Reefhuis J, Zhang Y, Sunderam S, Cohen B, et al. Assisted reproductive technology and birth defects among Liveborn infants in Florida, Massachusetts, and Michigan, 2000–2010. JAMA Pediatr. 2016;170(6):e154934.
- DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H, Macartney KK, et al. Congenital anomalies: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(49):6015.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH ("Springer Nature").

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users ("Users"), for smallscale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use ("Terms"). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

- 1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
- 2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
- 3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
- 4. use bots or other automated methods to access the content or redirect messages
- 5. override any security feature or exclusionary protocol; or
- 6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com